This year's BEBPA HCP Conference reaffirmed the importance of using orthogonal analytical methods to effectively assess and control HCPs across biopharmaceutical development. The BioGenes team was proud to participate and engage with industry peers and innovators.
Scientists and regulatory agencies agreed: Each analytical method offers unique strengths but also has its blind spots. Therefore, building a comprehensive fit-for-purpose analytical toolkit that combines complementary methods is good scientific practice.
At BioGenes, we provide a wide portfolio of these analytical tools and work closely with our partners to implement science- and risk-based strategies.